Company Information

  

Address: 450 EAST 29TH STREET  
City: NEW YORK 
State: NY 
Zip Code: 10016 
Telephone: 212-308-6000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our research and clinical development team members, who prior to joining Kadmon brought more than 15 drugs to market, to identify and develop our novel product candidates, through in¬≠licensing products and employing our small molecule and biologics platforms. By retaining global commercial rights to our clinical product candidates, we believe we have the ability to progress these candidates ourselves while maintaining flexibility for commercial and licensing arrangements. Below is a brief description of our lead product candidates: ¬∑ KD025. The most advanced candidate in our rho-associated coiled-coil kinase (ROCK) platform, KD025, is a potential first-in-class, oral, selective ROCK2 inhibitor.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-2.11NAN/E
03/2017-6.13NAN/E
12/2016-9.74NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-2.26Total Liab/Total Assets1.40
Net Inc/Total Assets-3.34Total Liab/Inv Cap2.44
Net Inc/Inv Cap-5.81Total Liab/Comm Equity0.95
Pretax Inc/Net Sales-8.00Interest Coverage Ratio-1.87
Net Inc/Net Sales-8.01Curr Debt/Equity-0.08
Cash Flow/Net Sales-2.03LTD/Equity-1.27
SG&A/NetSales3.91Total Debt/Equity-1.34
Asset Utilization   Liquidity  
Net Receivables Turnover11.32Quick Ratio1.55
Inventory Turnover1.43Current Ratio1.63
Inventory Day Sales0.01Net Rec/Curr Assets0.03
Net Sales/Work Cap1.68Inv/Curr Assets0.05
Net Sales/PP&E4.80  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 2.96 5.57 4.28 5.70
Cost of Goods Sold 0.64 0.94 0.76 1.01
Selling & Admin Exps 9.90 10.12 15.30 47.49
Operating Income -17.64 -13.94 -20.49 -52.27
Interest Exp 1.43 1.60 1.62 54.02
Pretax Income -22.31 -17.25 -22.20 -116.32
Other Income -0.15 0.92 1.26 -8.29
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -22.31 -17.57 -22.23 -116.32

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 26.23 43.05 36.09 55.00
Receivables - Total 1.61 1.76 1.21 1.67
Inventories - Total 1.14 1.62 1.95 2.28
Total Current Assets 31.11 48.57 40.29 59.88
Net Property, Plant & Equipment 5.09 5.16 5.43 5.97
Total Assets 47.33 67.95 62.56 86.80
Liabilities        
Accounts Payable 16.78 18.20 18.45 21.40
Debt in Current Liabilities 36.00 1.14 1.90 7.94
Total Current Liabilities 57.18 23.74 24.75 33.76
Long-Term Debt 0.00 34.17 31.98 29.47
Total Liabilities 85.61 87.56 87.75 95.56
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 39.24 38.77 38.30 37.83
Common Stock 0.05 0.05 0.05 0.05
Retained Earnings -196.52 -173.74 -155.71 -131.02
Treasury Stock NA NA NA NA
Total Stockholders' Equity -38.28 -19.62 -25.19 -8.76
Total Liabilities and Stockholders' Equity 47.33 67.95 62.56 86.80

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -15.94 -15.69 -15.16 -16.72
Net Cash Provided by Investing Activities -0.23 -0.08 -0.01 -0.11
Net Cash Provided by Financing Activities -0.66 22.73 -3.74 66.29

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201495.02-64.36--
12/201535.72-147.08--
12/201626.06-208.76-9.74
Growth Rates-47.63----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/175520,84327.48




Report Date : 10/23/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.